iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.5731
-0.0132 (-2.25%)
At close: Aug 12, 2025, 4:00 PM
0.5700
-0.0031 (-0.54%)
Pre-market: Aug 13, 2025, 6:21 AM EDT
iBio, Inc. Employees
iBio, Inc. had 16 employees as of June 30, 2024. The number of employees decreased by 10 or -38.46% compared to the previous year.
Employees
16
Change (1Y)
-10
Growth (1Y)
-38.46%
Revenue / Employee
$23,438
Profits / Employee
-$1,312,000
Market Cap
9.30M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 16 | -10 | -38.46% |
| Jun 30, 2023 | 26 | -80 | -75.47% |
| Jun 30, 2022 | 106 | 31 | 41.33% |
| Jun 30, 2021 | 75 | 24 | 47.06% |
| Jun 30, 2020 | 51 | -4 | -7.27% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IBIO News
- 7 weeks ago - iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - GlobeNewsWire
- 7 weeks ago - iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - GlobeNewsWire
- 2 months ago - iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - GlobeNewsWire
- 3 months ago - iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - GlobeNewsWire
- 3 months ago - iBio Reports Fiscal Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - iBio Raises $6.2 Million Through Warrant Inducement Transaction - GlobeNewsWire
- 4 months ago - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - GlobeNewsWire
- 4 months ago - iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - GlobeNewsWire